Niacin noncompetitively inhibits DGAT2 but not DGAT1 activity in HepG2 cells.
about
Niacin Alternatives for Dyslipidemia: Fool's Gold or Gold Mine? Part II: Novel Niacin MimeticsNiacin, an old drug with a new twistAtherogenic dyslipidemia in metabolic syndrome and type 2 diabetes: therapeutic options beyond statinsGPR109A and vascular inflammationThe therapeutic role of niacin in dyslipidemia managementNiacin stimulates adiponectin secretion through the GPR109A receptorAtherogenic dyslipidemia and combination pharmacotherapy in diabetes: recent clinical trials.Effect of fenofibrate and niacin on intrahepatic triglyceride content, very low-density lipoprotein kinetics, and insulin action in obese subjects with nonalcoholic fatty liver diseaseFuture of GPR109A agonists in the treatment of dyslipidaemia.Involvement and mechanism of DGAT2 upregulation in the pathogenesis of alcoholic fatty liver disease.Extended-release niacin acutely suppresses postprandial triglyceridemia.Niacin: another look at an underutilized lipid-lowering medication.Nicotinic acid inhibits progression of atherosclerosis in mice through its receptor GPR109A expressed by immune cells.Thematic review series: glycerolipids. DGAT enzymes and triacylglycerol biosynthesis.A unified framework for association analysis with multiple related phenotypes.Atheroprotective lipoprotein effects of a niacin-simvastatin combination compared to low- and high-dose simvastatin monotherapy.Overexpression of full-length cholesteryl ester transfer protein in SW872 cells reduces lipid accumulationEffects of niacin on atherosclerosis and vascular function.Lowering triglycerides to modify cardiovascular risk: will icosapent deliver?Effects of nicotinic acid on gene expression: potential mechanisms and implications for wanted and unwanted effects of the lipid-lowering drug.Liver fat reduction with niacin is influenced by DGAT-2 polymorphisms in hypertriglyceridemic patientsThe use of stable isotope-labeled glycerol and oleic acid to differentiate the hepatic functions of DGAT1 and -2Defective triglyceride biosynthesis in CETP-deficient SW872 cells.Niacin in cardiovascular disease: recent preclinical and clinical developmentsEffects of phenotypic and genotypic factors on the lipid responses to niacin in Chinese patients with dyslipidemia.Expression of Soluble Forms of Yeast Diacylglycerol Acyltransferase 2 That Integrate a Broad Range of Saturated Fatty Acids in Triacylglycerols.Nicotinic acid: an old drug with a promising futureNicotinic acid supplementation in diet favored intramuscular fat deposition and lipid metabolism in finishing steers.Fixed-dose combination of extended-release niacin plus simvastatin for lipid disorders.Animal models of catheter-induced intimal hyperplasia in type 1 and type 2 diabetes and the effects of pharmacologic intervention.Extended-release niacin alters the metabolism of plasma apolipoprotein (Apo) A-I and ApoB-containing lipoproteins.The mechanism and mitigation of niacin-induced flushing.Independent and combined effects of aerobic exercise and pharmacological strategies on serum triglyceride concentrations: a qualitative review.A new paradigm for managing dyslipidemia with combination therapy: laropiprant + niacin + simvastatin.Niacin, an old drug with new perspectives for the management of dyslipidaemia.Dyslipidaemia in the metabolic syndrome and type 2 diabetes: pathogenesis, priorities, pharmacotherapies.Atherosclerosis regression and high-density lipoproteins.New evidence for nicotinic acid treatment to reduce atherosclerosis.Emerging options in the treatment of dyslipidemias: a bright future?The facts behind niacin.
P2860
Q26765137-E85F1128-CF80-4E72-93E8-9A19CDA4C06BQ27002774-291DAE1E-1E3B-4B06-9817-5D3DAE62B290Q28200554-CF6CF01E-A011-4904-B937-7C8B012C72E0Q28287747-3B2D5A26-6776-4315-B1E6-28EA0FEACE46Q28304559-47ECF04F-9C43-42E7-8CE7-C5BC4F3A297DQ28575089-B9E1E55C-D5BA-402E-9519-37DD6D4BA9C0Q33776194-A2059E55-B766-462E-94E3-E5B6969F9883Q33984899-6D746AF5-7CC6-473F-8BFE-F0B30CDD1ADEQ34171831-BA49F76F-7517-4EB0-A20C-BC434EB48659Q34187979-A6C38060-AED0-431A-B237-DF19E1C3E597Q34223452-934C903E-FAD0-4E6E-945F-8749D1710569Q34255686-217F3DD4-325D-435E-B902-7EA09BFECE98Q34624990-AFAA67EF-7772-4162-9691-263E7B563B0FQ34817393-AAAB901B-38FF-4CDB-A39C-AD0A62AC0637Q34825206-6C936462-54E4-487D-B530-A5B6D55453AAQ34931247-DBD2D53A-37EB-4136-B0F6-02A36C9F53C1Q35120890-C254DD02-4AC5-46AB-9395-BBACCEDDE593Q35132366-B4D8F70C-4543-43B2-B212-A8F49AEAFE68Q35230819-8C0E0158-3387-4162-A1C9-B1C84470E9DCQ35432791-86388928-13EB-47BB-A0FA-04C787C26797Q35839709-38FD2146-BDE8-46DE-B68E-619C9752B472Q35958448-0EE9241F-EEF2-41EF-ABF8-85259CE4F511Q35994348-18050E0D-8380-4382-B815-4588A35C9D25Q36084389-A71A2088-A521-405F-AE6B-15A12CFDD887Q36152978-5D6C128F-53AA-4E87-A551-9CC341D0CE55Q36174116-1563082D-417D-4D50-B32F-A63DD4CC9F9FQ36497035-7737ECC8-EFF0-4913-BE66-7B0BEC147374Q37107041-63C3A520-29F1-4CA1-B44C-D6CB0989AD26Q37329136-397E7A5F-A855-4817-BC02-04488F539E05Q37367896-8D7D2DC9-063C-40C6-B920-7ACD626AC4A9Q37386911-74E3B52A-6745-47D3-B4AF-C385F5436FDDQ37582460-B25AEAF3-85C9-4A95-B966-01AC63969AAAQ37667487-5D6E0EBF-BBA3-4910-8E06-4395ED6AFB13Q37689135-1BCF08C5-7EFD-465C-A583-A0949DCDCE7AQ37725868-EEB4CDAB-0186-4A33-A889-A95F82E2AA15Q37772510-F348DD20-1EFD-42A0-8BB9-C2C30F324930Q37786650-FECB83D8-68D9-42CE-BD5C-B77E28D3A635Q37799365-FE30507F-5746-4163-8716-5B1ECE1F0592Q37842462-51A0ABA5-3562-46F2-9F2A-329A721D17F5Q37926768-D9548653-A649-49B8-8356-225EE472FBD4
P2860
Niacin noncompetitively inhibits DGAT2 but not DGAT1 activity in HepG2 cells.
description
2004 nî lūn-bûn
@nan
2004 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2004 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
name
Niacin noncompetitively inhibits DGAT2 but not DGAT1 activity in HepG2 cells.
@ast
Niacin noncompetitively inhibits DGAT2 but not DGAT1 activity in HepG2 cells.
@en
Niacin noncompetitively inhibits DGAT2 but not DGAT1 activity in HepG2 cells.
@nl
type
label
Niacin noncompetitively inhibits DGAT2 but not DGAT1 activity in HepG2 cells.
@ast
Niacin noncompetitively inhibits DGAT2 but not DGAT1 activity in HepG2 cells.
@en
Niacin noncompetitively inhibits DGAT2 but not DGAT1 activity in HepG2 cells.
@nl
prefLabel
Niacin noncompetitively inhibits DGAT2 but not DGAT1 activity in HepG2 cells.
@ast
Niacin noncompetitively inhibits DGAT2 but not DGAT1 activity in HepG2 cells.
@en
Niacin noncompetitively inhibits DGAT2 but not DGAT1 activity in HepG2 cells.
@nl
P2093
P2860
P1476
Niacin noncompetitively inhibits DGAT2 but not DGAT1 activity in HepG2 cells.
@en
P2093
Daming Zhu
Moti L Kashyap
S Tavintharan
Shobha H Ganji
Vaijinath S Kamanna
Yiding Xing
P2860
P304
P356
10.1194/JLR.M300403-JLR200
P577
2004-07-16T00:00:00Z